Media
| Press Releases
KBP Biosciences Is Successfully Selected into the “Raffles Family Office · Huru...
KBP Biosciences Co., Ltd. announced it is successfully selected into the “Raffles Family Office · Hu...
Jan 30, 2022
KBP Biosciences Announces First Patient Dosed in KBP-5074 Global Phase 3 Study i...
Dose administration for the first patient in CLARION-CKD (ClinicalTrials.gov Identifier: NCT04968184...
Jan 04, 2022
KBP Biosciences Presentation at the 18th Global CardioVascular Clinical Trialist...
The 18th Global CardioVascular Clinical Trialist Forum was held December 2-5, 2021. The conference g...
Dec 10, 2021